NEW_CURA-LEAF_1170x120_OCT

Eli Lilly and Co.

Lilly reports new data indicating rise in opioid use for migraine treatment

Lilly reports new data indicating rise in opioid use for migraine treatment

INDIANAPOLIS — Eli Lilly and Co. announced the upcoming presentation of data indicating rising rates of opioid use for the treatment of migraine based on results from the OVERCOME (Observational Survey of the Epidemiology, Treatment and Care of Migraine) study. These findings will be presented on Saturday, July 13, 2019, at the 61st Annual Scientific Meeting

Lilly helping people prepare for disasters, making meds available

Lilly helping people prepare for disasters, making meds available

INDIANAPOLIS —  The 2019 Atlantic hurricane season begins June 1. With natural disasters and extreme weather on the rise, it’s critical to be prepared and ready to respond. That’s why Eli Lilly and Co. and two leading disaster relief organizations – Healthcare Ready and Direct Relief – are working to help people prepare for disasters and

Lilly to introduce lower-priced insulin

Lilly to introduce lower-priced insulin

INDIANAPOLIS — Reinforcing their commitment to lower out-of-pocket costs for people who need insulin, Eli Lilly and Co. announced it will introduce a lower-priced version of Humalog (insulin lispro injection 100 units/mL) in the United States — providing people with diabetes an insulin option that will have a list price 50 percent lower than the current

Lilly to acquire Loxo Oncology

Lilly to acquire Loxo Oncology

INDIANAPOLIS — Eli Lilly and Co. and Loxo Oncology, Inc. today announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion. Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. The acquisition would be the largest and latest in a

Lilly’s Emgality gets FDA approval for the preventive treatment of migraine in adults

Lilly’s Emgality gets FDA approval for the preventive treatment of migraine in adults

INDIANAPOLIS — Eli Lilly and Co. announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults. Emgality offers a once-monthly, self-administered, subcutaneous injection. Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients. Emgality will be available to patients